

Q4 2007 Analyst and Investor Briefing

February 28, 2008

- **Sales** rose by 0.9% to €8.040m (Q4'06: €7,970m); Volume +4%, price +/-0%, currency -4%, portfolio +1%. Portfolio and currency adjusted sales increased by 4.6%.
- **Reported EBITDA** at €1,081m, up by 27.8% (Q4'06: €846m).
- **Underlying EBITDA** advanced by 13.0% to €1.422m (Q4'06: €1,258m).
- **Reported EBIT** up by 86.9% to €385m (Q4'06: €206m).
- **Net Special Items** of -€389m include: *HealthCare*: Total -€311m, mainly due to Schering integration costs (-€143m), Schering PPA (-€73m) and litigation (-€79m). *CropScience*: -€36 (restructuring); *MaterialScience*: -€42m (restructuring).
- **Underlying EBIT** rose by 24.4% to €774m (Q4'06: €622m).
- **Non-operating result** at -€179m (Q4'06: -€77m) including net interest expenses of €160m (Q4'06: €242m). Foreign currency gain of €48m in connection with financing activities. Q4'06 included gain (€236m) from divestiture of our stake in GE Bayer Silicones.
- **Income taxes** at -€149m (Q4'06: €130m). One-time tax expense of -€42m for future intercompany transactions to optimize financial structure in the group. Q4'06 income taxes of €130m included gain of €203m resulting from one-time recognition of deferred tax assets on loss carryforwards. Income tax paid at -€29m (Q4'06: -€30m).
- **Net income** at €67m down by 78.5% (Q4'06: €311m). **EPS** amounted to €0.11 (Q4'06: €0.41).
- **Core EPS** at €0.71 up 42% (Q4'06: €0.50).
- **Gross cash flow** improved by 34.2% to €1,021m (Q4'06: €761m). **Delta Working Capital** down by 39.1% to €446m. **Net cash flow (cont.)** at €1,467m (Q4'06: 1,493m). **Investments** at €737m (Q4'06: €792m). **Operating free cash flow (total)** at €732m (Q4'06: €786m).
- **Net debt** (total) qoq reduced by €536 to €12,184m. Net debt down by €5,355m since year end 2006.

| €million | Q4 2006 | | | | | | Q4 2007 | | | | | |
|--------------------|--------------|-------------|-------------------|-------------|---------------|-----------------|--------------|--------------|-------------------|-------------|---------------|-----------------|
| | Sales | EBITDA rep. | EBITDA underlying | EBIT rep. | Special Items | EBIT underlying | Sales | EBITDA rep. | EBITDA underlying | EBIT Rep. | Special Items | EBIT underlying |
| HealthCare | 3,782 | 469 | 796 | 187 | (274) | 461 | 3,800 | 658 | 922 | 273 | (311) | 584 |
| Pharma | 2,698 | 250 | 563 | 3 | (260) | 263 | 2,619 | 434 | 670 | 84 | (283) | 367 |
| Cons. Health | 1,084 | 219 | 233 | 184 | (14) | 198 | 1,181 | 224 | 252 | 189 | (28) | 217 |
| CropScience | 1,302 | 107 | 142 | (42) | (42) | 0 | 1,321 | 142 | 177 | 7 | (36) | 43 |
| Crop Protect. | 1,090 | 76 | 111 | (53) | (42) | (11) | 1,100 | 112 | 147 | (3) | (36) | 33 |
| ES/BS | 212 | 31 | 31 | 11 | 0 | 11 | 221 | 30 | 30 | 10 | 0 | 10 |
| MaterialSc. | 2,532 | 288 | 307 | 131 | (56) | 187 | 2,579 | 325 | 367 | 199 | (42) | 241 |
| Materials | 749 | 62 | 62 | 18 | 0 | 18 | 778 | 42 | 42 | 1 | 0 | 1 |
| Systems | 1,783 | 226 | 245 | 113 | (56) | 169 | 1,801 | 283 | 325 | 198 | (42) | 240 |
| Reconc. | 354 | (18) | 13 | (70) | (44) | (26) | 340 | (44) | (44) | (94) | 0 | (94) |
| Group | 7,970 | 846 | 1,258 | 206 | (416) | 622 | 8,040 | 1,081 | 1,422 | 385 | (389) | 774 |



Bayer Group sales and earnings forecast

We plan to raise Group sales by about 5% on a currency-adjusted basis and expect to further increase underlying EBITDA and underlying EBITDA margin. Our planning is based on an exchange rate of 1.45 US\$/€ (PY average rate 1.37 US\$/€). Special charges: approx. €650m (€400m-€450m thereof will be cash items). Capex: €1.7bn; D&A: €2.6bn, thereof depreciation on property, plant and equipment accounting for €1.2bn. R&D spending: approx. €2.8bn.

We continue to target an EBITDA margin before special items in excess of 22% in 2009.

HealthCare:

Targeting a growth at or above-market rate (on a Fx adj. basis) in all divisions in 2008, and an improvement in underlying EBITDA margin to approx. 27%. We confirm our target of an underlying EBITDA margin of around 28% in 2009.

CropScience

We expect a generally positive market environment in 2008 and aim to raise sales by approx. 5% on a currency-adjusted basis. Our goal is to improve the underlying EBITDA margin to > 23%. We plan to further increase our profitability by 2009 and continue to target an underlying EBITDA margin of around 25% in a normal market environment.

Bayer MaterialScience

We are planning to achieve good volume growth once again in 2008. Due to the uncertain business environment and highly volatile raw material prices, it is currently not possible to make a firm prediction concerning earnings for the full year. We expect to achieve a good, value-creating earnings level, though without matching the 2007 figure. For the first quarter of 2008 we believe underlying EBITDA will remain practically level with the fourth quarter of 2007. We continue to believe that in the future, under favorable economic conditions, we can post an underlying EBITDA margin of more than 18 %.

Q4'07 HealthCare

Pharmaceuticals sales -2.9% (Fx adj. +1.4%) to €2,619m compared to a strong Q4'06. YoY comparison affected by negative one-time effects of roughly €80m due to cessation of plasma products distribution, Helixate shipment fluctuations to CSL and absence of Cipro government sales included in Q4'06. *Primary Care*: Adalat (€155m, -10.9%, Fx adj. -7.2%). Avelox grew strongly by 29.3% to €128m (Fx adj. +35.5%) on higher volumes in US and EU. Cipro (€86m, -37.2%, Fx adj. -34.9%). Levitra down 4.7% (Fx adj. -0.1%) to €82m. *Women's HealthCare*: Yasmin sales (including Yaz and Yasminelle) rose by 20.2% (Fx adj. +27.2%) to €274m, driven by increasing market share in all regions. Mirena advanced by 14.3% to €96m (Fx adj. +19.7%), driven mainly by growth in the US market. *Diagnostic Imaging*: Magnevist fell 15.7% to €70m (Fx adj. -8.9%). Ultravist (€57m, +18.8%, Fx adj. +24.0%). *Specialized Therapeutics*: Betaferon rose by 0.8% (Fx adj. +3.9%) to €266m. *Hematology/Cardiology*: Kogenate dropped 5.4% (Fx adj. -1.4%) to €194m. Voluntary suspension of Trasylol (€10m, -75.0%, Fx adj. -71.1%) *Oncology*: Nexavar contributed €87m (+77.6%, Fx adj. +84.3%). Portfolio effect of Plasma (-€14m) due to termination of distribution in some regions in 2006.

Underlying EBITDA at €670m (Q4'06: €563m), up 19.0%, mainly due to synergies already achieved. **Underlying EBIT** up 39.5% to €367m. Cost base in Q4 approx. €130m higher compared to Q3, driven primarily by higher marketing cost. Reclassification of approx. €25m former Schering R&D cost per quarter (FY'07: approx. €100m) to marketing cost to align with Bayer accounting practices under IFRS.

Consumer Health sales up 8.9% to €1,181m (Fx adj. +14.6%). *Consumer Care*: Aspirin OTC advanced by 8.5% (Fx adj. +11.9%) to €128m, due to strong sales in all regions. Aleve up 10.7% to €62m (Fx adj. +21.3%), mainly due to new product launches (Liquid Gel). Canesten (€44m, +10.0%, Fx adj.



+15.7%). Bepanthen family grew by 16.7% to €35m (Fx adj. +13.3%). One-A-Day vitamin product fell by 5.7% (Fx adj. +4.5%) to €33m. Rennie increased sales by 3.6% (Fx adj. +3.3%) to €29m. *Diabetes Care*: Ascensia family expanded sales by 21.2% (Fx adj. +27.7%) to €257m, driven by strong performance in North America and Europe. *Animal Health*: Advantage family up 5.5% (Fx adj. +13.7%) to €58m.

Underlying EBITDA improved by 8.2% to €252m, due to the gratifying expansion of the business in all regions. **Underlying EBIT** increased by 9.6% to €217m.

Q4'07 CropScience

Crop Protection sales increased by 0.9% to €1,100m (Fx adj. +3.6%). Sales in the **Herbicides** business slightly dropped 1.8% to €372m (Fx adj. +0.8%). Good development in Asia (some rainfall in Australia stimulated sales) partly compensated for decline in Europe (lower pre-season sales in France) and GMO pressure in LatAm. **Fungicides** sales down 3.5% to €307m (Fx adj. -2.2%). Strong performance of Flint in LatAm could not fully offset phasing effects (Q4 to Q1) in Europe. **Insecticides** decreased by 3.8% to €276m (Fx adj. -1.1%). Favorable growth of new products in LatAm offset price pressure in NA. **Seed Treatment** strongly up by 36.8% to €145m (Fx adj. +43.2%). Increasing global corn acreage drives Poncho, especially in NA. **Underlying EBITDA** climbed by 32.4% to €147m, due to higher volumes and savings from restructuring programs. **Underlying EBIT** up by €44m to €33m.

Environmental Science/BioScience sales up by 4.2% (Fx adj. +8.7%) to €221m. **Environmental Science** down by 6.9% (Fx adj. -0.7%) to €148m, due to generic pressure for Professional Products and depressed housing market (effects termiticides) in NA nearly offset by good development in EU. Sales of **BioScience** unit advanced by 37.7% to €73m (Fx adj. +36.8%), driven by good performance of vegetable seeds and lower returns of canola seeds.

Underlying EBITDA fell by €1m to €30m. **Underlying EBIT** down by €1m to €10m.

Q4'07 MaterialScience

Materials segment sales moved ahead by 3.9% (Fx adj. +9.7%) to €778m due to higher Polycarbonates volumes and first-time consolidation of Ure-Tech (TPU). Polycarbonates sales up 2.9% (Fx adj. +8.9%) to €719m.

Underlying EBITDA dropped by 32.3% to €42m. Earnings burdened by higher raw material costs and negative Fx effects. **Underlying EBIT** down €17m to €1m.

Systems segment sales were slightly up 1.0% to €1,801m (Fx adj. +5.5%) with Polyurethanes contributing €1,280m (-0.3%). Demand for MDI remained solid (except USA), TDI showed strong volume and price growth. Coatings, Adhesives, Sealants continued to grow on higher prices and volumes (€380m, +7.3%).

Underlying EBITDA advanced by 32.7% to €325m. Higher selling prices fully compensated higher raw material costs and negative Fx effects. **Underlying EBIT** up by 42.0% to €240m.


Bayer Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
 Dr. Jürgen Beunink (+49-214-30-65742)
 Peter Dahlhoff (+49-214-30-33022)
 Ilia Kürten (+49-214-30-35426)
 Ute Menke (+49-214-30-33021)
 Judith Nestmann (+49-214-30-66836)
 Dr. Olaf Weber (+49-214-30-33567)

Forward-looking statements

This announcement may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Calculation of Core EBIT and Core Earnings per Share

| Calculation of Core EBIT and Core Earnings per Share  | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------|
| in € million | 2006 | 2007 | Q4'06 | Q4'07 |
| EBIT as per income statement | 2,762 | 3,154 | 206 | 385 |
| Amortization and write-downs of intangible assets | 734 | 1,463 | 267 | 366 |
| Write-downs of property, plant and equipment | 107 | 118 | 78 | 32 |
| Special items (other than write-downs) | 909 | 911 | 412 | 341 |
| Core EBIT | 4,512 | 5,646 | 963 | 1,124 |
| Non-operating result (as per income statement) | (782) | (920) | (77) | (179) |
| One-time income/losses from investments in affiliated companies | (236) | - | (236) | - |
| Income taxes (as per income statement) | (454) | 72 | 130 | (149) |
| One-time tax income | (203) | (870) | (203) | 41 |
| Tax adjustment | (531) | (887) | (180) | (270) |
| Income after taxes attributable to minority interest | (12) | (5) | (12) | (4) |
| Core net income from continuing operations | 2,294 | 3,036 | 385 | 563 |
| Financing expenses for the mandatory convertible bond, net of tax effects | 72 | 98 | 24 | 25 |
| Adjusted core net income | 2,366 | 3,134 | 409 | 588 |
| Adjusted weighted average total number of issued and potential ordinary shares | 791,757,583 | 823,907,303 | 823,865,730 | 823,927,413 |
| Core earnings per share from continuing operations (€) | 2.99 | 3.80 | 0.50 | 0.71 |